Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03931291
Title APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Aprea Therapeutics AB
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
H. Lee Moffitt Cancer Center & Research Institute Tampa Florida 33612 United States Details
Johns Hopkins, Sidney Kimmel Comprehensive Cancer Center Baltimore Maryland 21278 United States Details
Massachusetts General Hospital Boston Massachusetts 02114 United States Details
Dana Farber Cancer Institute Boston Massachusetts 02115 United States Details
Memorial Sloan Kettering Cancer Center New York New York 10065 United States Details
Vanderbilt Ingram Cancer Center Nashville Tennessee 37232 United States Details
Fred Hutchinson Cancer Center Seattle Washington 98109 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field